Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

Journal of Bone and Mineral Research

Volumn 32, Issue 9, 2017, Pages 1956-1962

  Keaveny, Tony M ^a   Crittenden, Daria B ^b   Bolognese, Michael A ^c   Genant, Harry K ^d   Engelke, Klaus ^e   Oliveri, Beatriz ^f   Brown, Jacques P ^g   Langdahl, Bente L ^h   Yan, Chris ⁱ   Grauer, Andreas ^b   Libanati, Cesar ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMGEN INC   (United States)

^c Bethesda Health Research Center   (United States)

^d SYNARC INC   (United States)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^g University Laval   (Canada)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ AMGEN LTD   (United Kingdom)

^j UCB PHARMA   (Belgium)

more..

Author keywords

ANABOLICS; OSTEOPOROSIS; ROMOSOZUMAB; TERIPARATIDE

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; ROMOSOZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BONE MASS; BONE STRENGTH; COMPARATIVE STUDY; CORTICAL BONE; FEMALE; FINITE ELEMENT ANALYSIS; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PROXIMAL FEMUR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINE; TRABECULAR BONE; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY; BONE DENSITY; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; LUMBAR VERTEBRA; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BONE DENSITY; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

EID: 85021336432     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3176     Document Type: Article

References (32)

1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25(10):2359–81.
2. Papapoulos S, Makras P. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2008; 4(9):514–23.
3. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res. 2010; 25(3):472–81.
4. Keaveny TM, Hoffmann PF, Singh M, et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008; 23(12):1974–82.
5. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012; 50(1):165–70.
6. Kleerekoper M, Greenspan SL, Lewiecki EM, et al. Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. J Bone Joint Surg Am. 2014; 96(11):e90.
7. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone. 2014; 67:246–56.
8. Ma YL, Zeng QQ, Chiang AY, et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone. 2014; 59:139–47.
9. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016; 375(16):1532–43.
10. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370(5):412–20.
11. Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017; 32(1):181–7.
12. Li X, Niu QT, Warmington KS, et al. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 2014; 155(12):4785–97.
13. Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2017; 32(4):788–801.
14. Lee DC, Varela A, Kostenuik PJ, Ominsky MS, Keaveny TM. Finite element analysis of denosumab treatment effects on vertebral strength in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2016; 31(8):1586–95.
15. Zysset P, Qin L, Lang T, et al. Clinical use of quantitative computed tomography-based finite element analysis of the hip and spine in the management of osteoporosis in adults: the 2015 ISCD Official Positions-Part II. J Clin Densitom. 2015; 18(3):359–92.
16. Keaveny TM, McClung MR, Genant HK, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014; 29(1):158–65.
17. Kopperdahl DL, Aspelund T, Hoffmann PF, et al. Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans. J Bone Miner Res. 2014; 29(3):570–80.
18. Eswaran SK, Bayraktar HH, Adams MF, et al. The micro-mechanics of cortical shell removal in the human vertebral body. Comput Methods Appl Mech Eng. 2007; 196:3025–32.
19. Eswaran SK, Gupta A, Adams MF, Keaveny TM. Cortical and trabecular load sharing in the human vertebral body. J Bone Miner Res. 2006; 21(2):307–14.
20. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18(11):1932–41.
21. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26(1):19–26.
22. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883–7.
23. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19(13):1842–4.
24. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6(10):e25900.
25. Amin S, Kopperdhal DL, Melton LJ 3rd, et al. Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res. 2011; 26(7):1593–600.
26. Anderson DE, Demissie S, Allaire BT, et al. The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture. Osteoporos Int. 2014; 25(2):559–66.
27. Danielson ME, Beck TJ, Karlamangla AS, et al. A comparison of DXA and CT based methods for estimating the strength of the femoral neck in post-menopausal women. Osteoporos Int. 2013; 24(4):1379–88.
28. Imai K, Ohnishi I, Matsumoto T, Yamamoto S, Nakamura K. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int. 2009; 20(5):801–10.
29. Keyak JH, Sigurdsson S, Karlsdottir G, et al. Male-female differences in the association between incident hip fracture and proximal femoral strength: a finite element analysis study. Bone. 2011; 48(6):1239–45.
30. Melton LJ 3rd, Riggs BL, Keaveny TM, et al. Structural determinants of vertebral fracture risk. J Bone Miner Res. 2007; 22(12):1885–92.
31. Melton LJ 3rd, Riggs BL, Keaveny TM, et al. Relation of vertebral deformities to bone density, structure, and strength. J Bone Miner Res. 2010; 25(9):1922–30.
32. Orwoll ES, Marshall LM, Nielson CM, et al. Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res. 2009; 24(3):475–83.